Dr. Alicia Morgans discusses unmet needs in patients with nmCRPC
"Nonmetastatic castration-resistant prostate cancer remains an incurable disease state," says Alicia Morgans, MD.
In this video, Alicia Morgans, MD, genitourinary medical oncologist, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Video Transcription
Nonmetastatic castration-resistant prostate cancer (nmCRPC) remains an incurable disease state. And certainly, when we think about where we want to go in the future, we need to think about ways to take incurable disease states, particularly ones with very limited metastatic burden, like a nonmetastatic CRPC patient population, and figure out if there are ways or can be ways that we can cure them of their currently incurable prostate cancer. And as time goes on, I do think the other big push that we have for our patients is to try to figure out if we might be able to limit the use of therapies that decrease testosterone, if that will be possible at some point in time. I think they'll all feel a lot better and certainly will be happy for the major paradigm shift that that would entail.
Transcription has been edited for clarity.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
